Dr. Reddy’s Laboratories announced that the US Food & Drug Administration (USFDA) has completed a GMP inspection at its API facility (CTO-SEZ) located in Srikakulam, Andhra Pradesh. The inspection was carried out from 10 November to 14 November 2025.
According to the company, the inspection closed with zero observations, indicating that no compliance issues were noted during the review. The update covers only the information shared by Dr. Reddy’s and reflects the status of the facility following the regulatory visit.
In the exchange filings, the company shared, “This is to inform you that the United States Food & Drug Administration (USFDA) today completed a GMP inspection at our API facility (CTO-SEZ) in Srikakulam, Andhra Pradesh. The inspection, carried out between 10th November and 14th November, 2025, has been concluded with zero observations.”
This development adds to the company’s routine regulatory disclosures and highlights the latest update regarding its manufacturing operations.
